These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 3469693)

  • 1. National Institutes of Health. Points to consider in the design and submission of human somatic-cell gene therapy protocols. Human Gene Therapy Subcommittee, NIH Recombinant DNA Advisory Committee. Adopted September 29, 1986.
    Recomb DNA Tech Bull; 1986 Dec; 9(4):221-42. PubMed ID: 3469693
    [No Abstract]   [Full Text] [Related]  

  • 2. Points to consider in the design and submission of human somatic cell gene therapy protocols.
    Recomb DNA Tech Bull; 1985 Dec; 8(4):181-6. PubMed ID: 3912845
    [No Abstract]   [Full Text] [Related]  

  • 3. Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Points to Consider Subcommittee. Minutes of meeting, March 31, 1989.
    Recomb DNA Tech Bull; 1989 Sep; 12(3):151-70. PubMed ID: 2595016
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a points to consider document for human somatic cell gene therapy.
    Milewski EA
    Recomb DNA Tech Bull; 1985 Dec; 8(4):176-80. PubMed ID: 3867980
    [No Abstract]   [Full Text] [Related]  

  • 5. Special informed consent requirements are included in protocol review procedures.
    Maloney DM
    Hum Res Rep; 1995 Jul; 10(7):1-2. PubMed ID: 11654274
    [No Abstract]   [Full Text] [Related]  

  • 6. Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee. Minutes of meeting, January 30, 1989.
    Recomb DNA Tech Bull; 1989 Jun; 12(2):69-134. PubMed ID: 2595015
    [No Abstract]   [Full Text] [Related]  

  • 7. NIH guidelines for research involving recombinant DNA molecules.
    Wilson DJ
    Account Res; 1993; 3(2-3):177-85. PubMed ID: 11652293
    [No Abstract]   [Full Text] [Related]  

  • 8. Department of Health and Human Services, Public Health Service, National Institutes of Health. Recombinant DNA Advisory Committee, Human Gene Therapy Subcommittee. Minutes of meeting, December 9, 1988.
    Recomb DNA Tech Bull; 1989 Mar; 12(1):29-45. PubMed ID: 2657876
    [No Abstract]   [Full Text] [Related]  

  • 9. The NIH trials of growth hormone for short stature.
    Tauer CA
    IRB; 1994 May; 16(3):1-9. PubMed ID: 11659923
    [No Abstract]   [Full Text] [Related]  

  • 10. The revised "Points to Consider" document.
    Hum Gene Ther; 1990; 1(1):93-103. PubMed ID: 2081190
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant DNA research; actions under guidelines; notice -- E. Points to consider for protocols for the transfer of recombinant DNA into the genome of human subjects.
    U.S. National Institutes of Health
    Fed Regist; 1990 Mar; 55(41):7443-7. PubMed ID: 11645685
    [No Abstract]   [Full Text] [Related]  

  • 12. Ethical issues in clinical neurological research.
    Shore D; Berg K; Mullican C
    J Calif Alliance Ment Ill; 1994; 5(1):61-2. PubMed ID: 11653329
    [No Abstract]   [Full Text] [Related]  

  • 13. The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
    Weijer C
    IRB; 1998; 20(2-3):1-5. PubMed ID: 11656912
    [No Abstract]   [Full Text] [Related]  

  • 14. Human Gene Therapy Subcommittee: minutes of meeting, 29-30 Jul 1991.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommittee
    Hum Gene Ther; 1992 Aug; 3(4):439-55. PubMed ID: 11643020
    [No Abstract]   [Full Text] [Related]  

  • 15. The regulation of human experimentation in the United States--a personal odyssey.
    Katz J
    IRB; 1987; 9(1):1-6. PubMed ID: 11649890
    [No Abstract]   [Full Text] [Related]  

  • 16. Toward a more comprehensive approach to protecting human subjects: the interface of data safety monitoring boards and institutional review boards in randomized clinical trials.
    Gordon VM; Sugarman J; Kass N
    IRB; 1998; 20(1):1-5. PubMed ID: 11655324
    [No Abstract]   [Full Text] [Related]  

  • 17. Gene therapy: proceed with caution.
    Grobstein C; Flower M
    Hastings Cent Rep; 1984 Apr; 14(2):13-7. PubMed ID: 6373668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant DNA research; request for public comment on "Points to consider in the design and submission of human somatic-cell gene therapy protocols.
    U.S. National Institutes of Health
    Fed Regist; 1985 Jan; 50(14):2940-5. PubMed ID: 11645541
    [No Abstract]   [Full Text] [Related]  

  • 19. Human Gene Therapy Subcommittee: minutes of meeting, 1 Jun 1990.
    U.S. National Institutes of Health. Recombinant DNA Advisory Committee. Human Gene Therapy Subcommittee
    Hum Gene Ther; 1991; 2(1):87-96. PubMed ID: 11642891
    [No Abstract]   [Full Text] [Related]  

  • 20. The concept of the IRB and bureaucratic reality: an exchange of letters.
    van Eys J; Levine RJ
    IRB; 1984; 6(4):8-10. PubMed ID: 11649563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.